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Background: Abdominal and thoracic aortic aneurysms (A/TAA) are an important cause of mortality amongst the
older population. Although A/TAA repair can be performed with low peri-operative risk, overall life expectancy remains
poor in the years that follow surgery. The majority of deaths are caused by heart attack or stroke, which can both be
prevented by cardiac rehabilitation (CR) in patients with clinically-manifest coronary artery disease. A Cochrane review
has urged researchers to widen the use of CR to other populations with severe cardiovascular risk, and patients
surviving A/TAA repair appear ideal candidates. However, it is unknown whether CR is feasible or acceptable to A/TAA
patients, who are a decade older than those currently enrolling in CR. Aneurysm-CaRe is a feasibility randomised
controlled trial (RCT) that will address these issues.
Methods and design: Aneurysm-CaRe is a pilot RCT of CR versus standard care after A/TAA repair, with the primary
objectives of estimating enrolment to a trial of CR after A/TAA repair and estimating compliance with CR amongst
patients with A/TAA. Aneurysm-CaRe will randomise 84 patients at two sites. Patients discharged from hospital after
elective A/TAA repair will be randomised to standard care or enrolment in their local CR programme with a protocolised
approach to medical cardiovascular risk reduction. The primary outcome measures are enrolment in the RCT and
compliance with CR. Secondary outcomes will include phenotypic markers of cardiovascular risk and smoking cessation,
alongside disease-specific and generic quality-of-life measures.
Trial registration: ISRCTN 65746249 5 June 2014
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Abdominal and thoracic aortic aneurysms (A/TAAs) are a
significant health problem that account for approximately
4 deaths per 100,000 population per year [1]. A/TAA re-
pair can be performed with low peri-operative risk [2] and
is an effective means of mitigating the long-term risk of
mortality caused by A/TAA rupture. However, overall life
expectancy remains poor in the years that follow surgery
because patients with A/TAA have widespread athero-
sclerosis and considerable cardiovascular risk factors,* Correspondence: pholt@sgul.ac.uk
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unless otherwise stated.which cause an unusually high rate of heart attacks,
strokes and major amputation [3] compared with the
wider population [4,5].
Patients with A/TAA have similar cardiovascular risk
factors to those with clinically-manifest coronary artery
disease (CAD) and might benefit from the application of
similar therapeutic strategies for secondary prevention.
High-quality evidence has demonstrated that cardiac
rehabilitation (CR) improves outcomes after cardiac sur-
gery or myocardial infarction, improving adherence to
evidence-based care and both the quality and quantity of
life [6]. CR is a complex intervention delivered typically
over 8–12 weeks, which combines supervised exercise,
dietary and lifestyle modification, smoking cessation, and
optimal medical therapy for cardiovascular risk factors.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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economic intervention for reducing cardiovascular mortal-
ity, after aspirin and beta-blockers [7]. Extensive national
infrastructure is in place for delivering this service, and a
Cochrane review has urged researchers to apply CR in
other populations with severe cardiovascular disease [6].
Patients undergoing A/TAA repair appear ideal candi-
dates for postoperative CR and are at even greater risk
of cardiovascular mortality than patients undergoing
cardiac surgery: just 65% remain alive at 5 years after
aneurysm repair [8] compared with 90% at 5 years after
cardiac surgery [9]. The definitive impact of CR on
survival after A/TAA repair could be studied by a
multicentre randomised trial of CR after A/TAA repair.
This would require 1140 patients to demonstrate an
absolute improvement of 9% in 3-year survival, with 90%
power, a calculation aiming to bridge the gap in survival
between A/TAA patients and age-/gender-matched
controls without A/TAA [4]. However, prior to such a
considerable undertaking, data are required to estimate
the feasibility and efficacy of CR in A/TAA patients.
Aneurysm-CaRe is a pilot randomised controlled trial of
CR after A/TAA repair that will address these issues.
Patients undergoing A/TAA repair are typically 10 years
older than those currently recruited to CR [4,6] and it is
therefore not known whether CR would be feasible or
acceptable in this group. It also remains unknown whether
an intensive programme of CR can improve phenotypic
markers of cardiovascular risk after A/TAA repair. The
life expectancy of patients with A/TAA may not be
modifiable by CR and the equipoise justifies a trial such
as Aneurysm-CaRe. Cigarette smoking is strongly asso-
ciated with the development of A/TAA and is the most
important modifiable risk factor for patients with
vascular disease [10]. The period after A/TAA surgery
presents a unique window for preventing a return to
smoking [11] and enrolment in a CR programme pro-
vides a novel opportunity for quantifying the effects of
exercise on smoking cessation in patients with A/TAA
[12]. Standard care may provide as few as 40% of
A/TAA patients with appropriate cardiovascular risk man-
agement (using antiplatelet agents, statins, angiotensin-
converting enzyme inhibitors or beta-blockers) [13] and it
is likely that attainment of risk-factor targets is even lower
than in comparable CAD populations. These data highlight
an unmet clinical need. Aneurysm-CaRe presents an
important opportunity to improve life expectancy in a
high-risk population (A/TAA patients) using an existing
national service (CR) and the accompanying infrastructure.
Methods
Trial design and objectives
Aneurysm-CaRe is a pilot randomised controlled trial
comparing CR with standard care after elective A/TAArepair. It is envisaged that this study will inform
Aneurysm-CaRe II: a large-scale definitive phase III ran-
domised controlled trial of CR after elective A/TAA
repair.
The objectives of Aneurysm-CaRe are to quantify the
proportion of patients surviving A/TAA repair that agree
to enrol in a RCT of CR and to quantify compliance
with CR in terms of attendance amongst those rando-
mised to CR. The secondary objectives of Aneurysm-
CaRe are to quantify the effect of CR compared with
standard care on phenotypic markers of cardiovascular
risk, patient behaviour/biometrics and quality of life.
Finally, Aneurysm-CaRe aims to enable optimisation of
the patient pathway for a definitive RCT and identifica-
tion of pitfalls such as exposure bias or methodological
heterogeneity.
Ethical approval
Full ethical approval has been gained from the NRES
Committee London (Bloomsbury), reference 13/LO/0395.
Funding
Aneurysm-CaRe is supported by a British Heart Founda-
tion Project Grant (PG/13/98/30490).
Randomisation
Patients discharged from hospital after elective endo-
vascular or open thoracic or abdominal aortic aneurysm
repair will be randomised, in a 1:1 ratio, between the
intervention arm (“Cardiac Rehabilitation – CR”) and
the control arm (“Standard Care”) (Figure 1). Secure
Internet-based central randomisation will be provided by
an NIHR-accredited clinical trials unit. A minimisation
algorithm will be utilised to ensure stratification vari-
ables (age, gender and study site) are balanced between
groups. Each site and randomiser will be provided with a
unique login and password to allow access to the ran-
domisation service.
Inclusion criteria
All patients who are discharged home alive after under-
going elective thoracic or abdominal aortic aneurysm re-
pair at St George’s Vascular Institute or Leicester Royal
Infirmary during the recruitment period will be eligible
for participation and offered the chance to enrol.
Exclusion criteria
The exclusion criteria are:
1. Any patient under the age of 50 years, or with aortic
pathology secondary to connective tissue disease
(including Marfan’s and Loeys-Dietz syndromes)
2. Anyone unable or unwilling to consent to
participation
Figure 1 CONSORT 2010 flow diagram for pilot randomised controlled trial of cardiac rehabilitation vs. standard care after aortic aneurysm
repair (Aneurysm-CaRe).
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4. Any patient deemed too unfit for the CR
programme by the Lead CR nurse
5. Patients undergoing expedited or emergent surgical
intervention for symptomatic or ruptured aortic
aneurysms
A pseudonymised registry will be kept to record the
proportion of patients undergoing elective aneurysm re-
pair but meeting exclusion criteria for Aneurysm-CaRe
during the study period.
Primary outcome measures
1. Enrolment: the proportion of patients surviving
A/TAA repair and meeting Aneurysm CaReinclusion criteria, that agree to enrolment in the
feasibility RCT.
2. Compliance with CR therapy in the group randomised
to CR (defined as the proportion of patients
demonstrating attendance at 100% of scheduled CR
sessions over 8–12 weeks; the period of CR offered is
dependent on individual patient needs).
Secondary outcome measures
1. Time to death.
2. Time to first adverse cardiovascular event after
aneurysm repair.
The composite “adverse cardiovascular event”
outcome includes: non-fatal myocardial infarction,
stroke, non-traumatic amputation and
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comprises strictly defined coronary procedures
(coronary artery bypass graft surgery, percutaneous
coronary interventions and percutaneous coronary
interventions) and peripheral vascular procedures
(embolectomy, bypass and angioplasty). In the
absence of relevant COMET outcomes (www.comet-
initiative.org), this outcome measure mirrors the
composite cardiovascular endpoint measured for
previous randomised RCTs of cardiovascular risk
reduction [14]. Analysis of the “composite
cardiovascular disease event” endpoint will be
adjusted to account for “competing risks”, for
example, the intervention reducing the risk of one
event but increasing the risk of another [15].
Outcomes will be compared with the BHF-funded
National Audit of CR for attendance, adherence, and
outcomes with MI, PCI and CABG patients.
3. Intermediate phenotypic markers of cardiovascular risk
measured at enrolment, 12-weeks after randomisation
to CR and 6-months after randomisation to CR or
standard care: serum lipids (total cholesterol, HDL and
LDL), systolic and diastolic blood pressure, HbA1C,
BNP, troponin, hsCRP, fibrinogen, homocysteine, urate,
eGFR, serum insulin levels and echocardiographic
measures of cardiac function. We will also be testing
for urinary microalbuminuria at each time point.
4. Indicators of patient behaviour and lifestyle, and
patient biometrics, including: waist:hip ratio, waist
circumference, BMI, ankle-brachial pressure index
(ABPI) and toe pressures. Smoking cessation outcomes
will include: salivary cotinine, expiratory carbon
monoxide (<10 ppm), “prolonged abstinence” [16] and
attendance at NHS stop-smoking services. Physical
activity levels will be assessed by a 7-day-recall
interview [17].
5. Changes in patients’ attitudes to cardiovascular risk
and their knowledge of their condition.
6. Quality of life: EQ5D5L questionnaires will be
administered at baseline, enrolment, 12-weeks after
randomisation to CR or standard care and 6 months
after randomisation to CR or standard care.
7. Cost-effectiveness: Mean costs and quality adjusted
life years will be compared on an intention-to-treat
basis. The perspective will be the NHS and PSS. The
analysis will include hospital re-admissions and
pharmaceuticals. Unit cost will be obtained from the
published literature.
Power calculation
A pilot RCT of 84 patients is planned; to estimate enrol-
ment rates in the trial, we plan to approach 140 patients
for consent. We expect that at least 60% (95% confi-
dence interval 50.7%-68.8%) will agree to enrolment,leading to the randomised study of 84 patients. The
lower margin of the 95% confidence interval for this
enrolment rate (50.7%) provides adequate precision to
establish that at least 50% of aortic aneurysm patients
will agree to participate in an RCT of CR; establishing
the feasibility of a definitive multi-centre national RCT.
The study will cease recruitment when either 84 patients
have been randomised or 140 patients approached. The
feasibility trial is itself feasible because St George’s and
Leicester perform in excess of 200 thoracic or abdominal
aneurysm repairs per annum. The target enrolment is
realistic because previous RCTs of A/TAA surgery in the
UK have reported 74-76% enrolment rates (EVAR-1 and
EVAR-2; NIHR HTA trials [18,19]).
Patient pathway
The pathway is outlined in Figures 1, 2 and 3.
Informed consent
Patients will be identified and given information about the
trial from three settings and seen by the local Principal
Investigator, a Research Investigator or the Lead CR Nurse:
1. At the surgical outpatient clinic when it is certain
that aortic aneurysm repair will be scheduled. The
trial will be discussed with the patient and the
patient given a Patient Information Sheet.
2. At the pre-operative assessment clinic.
3. On admission for surgery, prior to aortic aneurysm
repair.
Formal written consent will be obtained after the pa-
tient has undergone aortic aneurysm repair and been
deemed fit for discharge from hospital.
Randomisation
After informed consent has been obtained, a nominated
research investigator will randomise the patient using a
secure online NIHR-accredited Clinical Trials Unit
Randomisation Service (King’s Clinical Trials Unit). The
patient will be allocated a unique trial identification PIN
number. Neither investigators nor patients will be
blinded to treatment allocation. The patient’s GP will be
notified of the treatment allocation, and supplied with a
reminder letter highlighting current NICE guidelines for
the medical management of cardiovascular risk in
patients with peripheral vascular disease.
Treatment and follow-up
Patients randomised to CR will be seen by a member
of the Cardiac Rehabilitation team on the ward prior
to discharge if possible, or at the induction CR meet-
ing scheduled 4–6 weeks after aortic aneurysm repair.
The CR Arm will receive a protocolised approach to
Figure 2 Patient pathway.
Figure 3 Protocol for medical management of cardiovascular risk factors in patients randomised to CR group.
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addition to enrolment in the local multimodal Cardiac
Rehabilitation programme, which should follow national
guidelines (www.cardiacrehabilitation.org.uk). CR is an
existing national service, comprising a protocolised 8–12
week regime of supervised exercise, lifestyle modification,
dietary interventions, psychological assessment and med-
ical risk modification. Each weekly session takes 1 to 2 h
and is supervised by two nurses trained in CR, two quali-
fied physiotherapists and one occupational therapy techni-
cian. Patients assessed as being low-risk attend sessions
with a maximum of 20 patients; those deemed high-risk
attend sessions with 12 patients. Each session begins with
a “check-in” consisting of a blood pressure and heart rate
check and a review of each patient’s progress to date.
The group then proceed through a supervised warm-up of
10–15 min, followed by the main exercise session of
45 min. This is followed by a warm-down, and finally a
“check-out” consisting of further blood pressure and heart
rate measurement.
An individual assessment is made of each patient’s pro-
gress and needs; in some cases this involves extending the
duration of the patient’s participation in the programme
beyond the initial 8 weeks. The patients that have been
randomised to “treatment as usual” will receive “standard”
follow-up, i.e. routine post-operative out-patient appoint-
ments and/or follow-up scans as necessary and GP-based
management of their co-existing co-morbidities such as
hypertension. Local standards for routine outpatient care
after A/TAA repair will be unaffected by the trial, includ-
ing existing appointments for endograft surveillance and
vascular surgery outpatient review.
Patients in both arms of the study will undergo blood
tests, urinalysis, salivary testing, biometric assessment
and quality-of-life assessment at 6 weeks after surgery
(entry to CR in the CR group) (Figure 2). These tests will
be repeated, in addition to follow-up echocardiography,
in all patients at 12 weeks after randomisation to CR (or
12 weeks after surgery for those randomised to standard
care) and 6 months after randomisation into CR (or
6 months after surgery for “standard care” patients).
– Blood tests will comprise hsCRP, troponin, BNP,
lipid profile, fibrinogen, urate, eGFR, HBA1C and
serum insulin.
– Patients who smoke will have salivary cotinine testing
conducted and breath carbon monoxide testing on
entry to CR (or 6 weeks after randomisation in the
standard care group), 12-weeks after randomisation to
CR and at 6-month follow-up.
Discussion
Given that this study straddles specialties, particularly car-
diology and vascular surgery, an extensive collaborativeapproach has been employed to the benefit of the study
design and patient pathway. Pragmatically, rather than try-
ing to standardise the cardiac rehabilitation (CR) received
by patients not only at the two sites, but also at individual
CR locations within those sites, we have adopted the view
that the existing programmes at each venue will be
followed. National CR guidelines are already in place.
An electronic Case Report Form (CRF) has been
developed in conjunction with the Kings College Clinical
Trials (KCTU) unit to ensure consistency in data input-
ting and to streamline the analysis of results. This will
also allow assessment of the practicalities of using such
an electronic database across multiple sites. Randomisa-
tion will be carried out electronically using an online
randomisation tool developed by KCTU that is access-
ible at both sites. A Trial Manager has been appointed
to oversee the study, based at St George’s.
Trial status
This trial commenced recruiting patients in September
2014 at both sites.
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